152 patients enrolled TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a…
AvailTM trial exceeded enrollment target; topline results expected in Q3 2025CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences,…
Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor…
Boston (March 3, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to…
Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern TimeYAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE)…
Naxitamab demonstrated clinically meaningful efficacy with manageable safety in patients with relapsed/refractory high-risk neuroblastoma and residual disease in bone/bone marrowNEW…
Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement…
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology…
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of…